News | June 01, 2021
Marksans Pharma Q4 FY21 profit up 86%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The GMP certificate is valid for three years until April 2024.
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Subscribe To Our Newsletter & Stay Updated
